Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Integrative genomics identifies the molecular basis of resistance to azacitidine therapy in myelodysplastic syndromes

Myelodysplastic syndromes and chronic myelomonocytic leukemia are blood disorders characterized by ineffective hematopoiesis and progressive marrow failure that can transform into acute leukemia. The DNA methyltransferase inhibitor 5-azacytidine (AZA) is the most effective pharmacological option, bu...

Podrobná bibliografie
Hlavní autoři:	Unnikrishnan, A, Deshpande, NP, Verma, A, Kumari, A, Richards, LA, Knezevic, K, Chandrakanthan, V, Thoms, JAI, Tursky, ML, Huang, Y, Ali, Z, Olivier, J, Galbraith, S, Kulasekararaj, AG, Tobiasson, M, Karimi, M, Pellagatti, A, Wilson, SR, Lindeman, R, Young, B, Ramakrishna, R, Arthur, C, Stark, R, Crispin, P, Curnow, J, Warburton, P, Roncolato, F, Boultwood, J, Lynch, K, Jacobsen, SEW, Mufti, GJ, Hellstrom-Lindberg, E, Wilkins, MR, MacKenzie, KL, Wong, JWH, Campbell, PJ, Pimanda, JE
Médium:	Journal article
Jazyk:	English
Vydáno:	Cell Press 2017

Podobné jednotky

Myelodysplastic syndromes: moving towards personalized management
Autor: Eva Hellström-Lindberg, a další
Vydáno: (2020-07-01)

Spliceosome mutations: 1 plus 1 does not always equal 2
Autor: Pellagatti, A, a další
Vydáno: (2020)

Reduced translation of GATA1 in Diamond-Blackfan anemia.
Autor: Boultwood, J, a další
Vydáno: (2014)

SF3B1 mutant myelodysplastic syndrome: Recent advances
Autor: Pellagatti, A, a další
Vydáno: (2020)

Splicing factor gene mutations in the myelodysplastic syndromes: impact on disease phenotype and therapeutic applications.
Autor: Pellagatti, A, a další
Vydáno: (2016)

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression.
Autor: Jädersten, M, a další
Vydáno: (2009)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
Autor: Follo, M, a další
Vydáno: (2019)

P557: HEMATOLOGIC IMPROVEMENTS WITH IVOSIDENIB + AZACITIDINE COMPARED WITH PLACEBO + AZACITIDINE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA
Autor: H. Dohner, a další
Vydáno: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk myelodysplastic syndrome: the Phase 3, randomized, ENHANCE Study
Autor: Garcia-Manero, G, a další
Vydáno: (2021)

Haploinsufficiency of ribosomal proteins and p53 activation in anemia: Diamond-Blackfan anemia and the 5q- syndrome.
Autor: Boultwood, J, a další
Vydáno: (2012)

5q- syndrome.
Autor: Boultwood, J, a další
Vydáno: (2012)

A pilot phase I dose finding safety study of the thrombopoietin-receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine.
Autor: Svensson, T, a další
Vydáno: (2014)

P556: CHANGES IN HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA RECEIVING IVOSIDENIB + AZACITIDINE OR PLACEBO + AZACITIDINE
Autor: A. Schuh, a další
Vydáno: (2022-06-01)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): the phase 3, randomized, ENHANCE study
Autor: Garcia-Manero, G, a další
Vydáno: (2021)

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndromes (MDS): the Phase 3, randomized, ENHANCE Study
Autor: Garcia-Manero, G, a další
Vydáno: (2021)

PHASE 2 STUDY OF PEVONEDISTAT + AZACITIDINE VERSUS AZACITIDINE IN PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES/CHRONIC MYELOMONOCYTIC LEUKEMIA OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA (NCT02610777)
Autor: L. Adès, a další
Vydáno: (2020-11-01)

P430: MOLECULAR CHARACTERIZATION OF CLINICAL RESPONSE IN NEWLY-DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS TREATED WITH IVOSIDENIB + AZACITIDINE COMPARED TO PLACEBO + AZACITIDINE
Autor: S. de Botton, a další
Vydáno: (2022-06-01)

Gene expression profiling of day 7 erythroblasts from RARS before and after treatment with G-CSF
Autor: Nikpour, M, a další
Vydáno: (2007)

Deregulated Gene Expression Pathways in Myelodysplastic Syndrome Hematopoietic Stem Cells
Autor: Pellagatti, A, a další
Vydáno: (2009)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Autor: R Edlin, a další
Vydáno: (2010-05-01)

Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Autor: R Edlin, a další
Vydáno: (2010-05-01)

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML
Autor: A. Schnegg-Kaufmann, a další
Vydáno: (2022-06-01)

MDS-197: Magrolimab + azacitidine versus azacitidine + placebo in untreated higher-risk (HR) myelodysplastic syndromes (MDS): the phase 3, randomized, ENHANCE study
Autor: Garcia-Manero, G, a další
Vydáno: (2021)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes (British Journal of Haematology (2008) 142, (57-64))
Autor: Pellagatti, A, a další
Vydáno: (2009)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome.
Autor: Pellagatti, A, a další
Vydáno: (2011)

Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells
Autor: Pellagatti, A, a další
Vydáno: (2010)

Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes.
Autor: Pellagatti, A, a další
Vydáno: (2008)

Marked down-regulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome
Autor: Pellagatti, A, a další
Vydáno: (2011)

Del(5q) Myelodysplastic Stem Cells Exhibit Their Clonal Advantage Via Increased Adhesion to the Microenvironment
Autor: Scharenberg, C, a další
Vydáno: (2011)

Gene expression profiling in the myelodysplastic syndromes.
Autor: Pellagatti, A, a další
Vydáno: (2005)

A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes
Autor: Sara Mongiorgi, a další
Vydáno: (2023-02-01)

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches
Autor: Armstrong, R, a další
Vydáno: (2017)

Advances in the 5q- syndrome.
Autor: Boultwood, J, a další
Vydáno: (2010)

Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.
Autor: Pellagatti, A, a další
Vydáno: (2010)

The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?
Autor: Anjali Bhatt, a další
Vydáno: (2022-11-01)

A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine
Autor: Chiara R. Dart, a další
Vydáno: (2021-07-01)

NEW INSIGHTS INTO THE BIOLOGY OF REFRACTORY ANEMIA WITH RING SIDEROBLASTS (RARS) AND IDENTIFICATION OF ERYTHROID G-CSF TARGETS BY GENE EXPRESSION PROFILING
Autor: Nikpour, M, a další
Vydáno: (2009)

YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
Autor: Nikpour, M, a další
Vydáno: (2009)

Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets
Autor: Nikpour, M, a další
Vydáno: (2009)

Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of G-CSF.
Autor: Nikpour, M, a další
Vydáno: (2010)